Suppr超能文献

接受持续肾脏替代治疗患者的拉科酰胺给药方案。

Lacosamide dosing in patients receiving continuous renal replacement therapy.

作者信息

Chaijamorn Weerachai, Phunpon Sathian, Sathienluckana Thanompong, Charoensareerat Taniya, Pattharachayakul Sutthiporn, Rungkitwattanakul Dhakrit, Srisawat Nattachai

机构信息

Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathum Wan, Bangkok, 10330, Thailand.

Faculty of Pharmacy, Siam University, Bangkok, Thailand.

出版信息

J Intensive Care. 2023 Nov 9;11(1):50. doi: 10.1186/s40560-023-00700-4.

Abstract

BACKGROUND

Lacosamide is one of the anticonvulsants used in critically ill patients. This study aimed to suggest appropriate lacosamide dosing regimens in critically ill patients receiving continuous renal replacement therapy (CRRT) via Monte Carlo simulations.

METHODS

Mathematical models were created using published demographic and pharmacokinetics in adult critically ill patients. CRRT modalities with different effluent rates were added into the models. Lacosamide regimens were evaluated on the probability of target attainment (PTA) using pharmacodynamic targets of trough concentrations and area under the curve within a range of 5-10 mg/L and 80.25-143 and 143-231 mg*h/L for the initial 72 h-therapy, respectively. Optimal regimens were defined from regimens that yielded the highest PTA. Each dosing regimen was tested in a group of different 10,000 virtual patients.

RESULTS

Our results revealed the optimal lacosamide dosing regimen of 300-450 mg/day is recommended for adult patients receiving both CRRT modalities with 20-25 effluent rates. The dose of 600 mg/day was suggested in higher effluent rate of 35 mL/kg/h. Moreover, a patient with body weight > 100 kg was less likely to attain the targets.

CONCLUSIONS

Volume of distribution, total clearance, CRRT clearance and body weight were significantly contributed to lacosamide dosing. Clinical validation of the finding is strongly indicated.

摘要

背景

拉科酰胺是用于重症患者的抗惊厥药物之一。本研究旨在通过蒙特卡洛模拟,为接受持续肾脏替代疗法(CRRT)的重症患者推荐合适的拉科酰胺给药方案。

方法

利用已发表的成年重症患者的人口统计学和药代动力学数据建立数学模型。将不同流出率的CRRT模式添加到模型中。根据治疗最初72小时内谷浓度和曲线下面积的药效学目标,分别在5 - 10mg/L以及80.25 - 143和143 - 231mg*h/L范围内,通过目标达成概率(PTA)评估拉科酰胺给药方案。从产生最高PTA的方案中确定最佳方案。每个给药方案在一组10,000名不同的虚拟患者中进行测试。

结果

我们的结果显示,对于接受流出率为20 - 25的两种CRRT模式的成年患者,推荐的拉科酰胺最佳给药方案为300 - 450mg/天。在流出率较高(35mL/kg/h)的情况下,建议剂量为600mg/天。此外,体重>100kg的患者达到目标的可能性较小。

结论

分布容积、总清除率、CRRT清除率和体重对拉科酰胺给药有显著影响。强烈建议对这一发现进行临床验证。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验